Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.ID Biomedical cleared for US Fluviral testing
The company intends to ship product to the US and initiate enrollment of subjects before the end of January 2005. The Fluviral vaccine to be tested was produced
The company intends to ship product to the US and initiate enrollment of subjects before the end of January 2005. The Fluviral vaccine to be tested was produced
Enrollment in Inhibitex’ ongoing phase III clinical trial of Veronate for the prevention of hospital-associated infections in very low birth weight infants has outpaced the company’s initial expectations
Under the agreement, Cambrex will provide process development and cGMP (current good manufacturing processes) production services for RiVax. Ricin toxin is a potential bioterror threat due to its
In conjunction with the research agreement, Ziopharm also signed a two-year option agreement to enter into an exclusive worldwide license agreement for these novel alkylating agents. A patent
The primary objective of the multi-center, open-label, non-randomized phase II trial is to evaluate tumor response (the level of anti-tumor activity of EOquin), with time to recurrence and
The updated product label comes as a follow-up to the letter issued to healthcare providers in August 2004 regarding an increased risk of arterial thromboembolic events (ATEs) associated
The International Federation of Pharmaceutical Manufacturers and Associations (IFPMA) has jointly developed these principles of disclosure together with three other industry associations: the European Federation of Pharmaceutical Industries
At merger, the enlarged company will have cash reserves of GBP11 million, approximately half of which is new investment secured from existing investors, Bio-1 Capital, Merlin Biosciences and
The investigator-initiated study, which was published in medical journal The Lancet, is the largest clinical trial to date with peginterferon alfa-2b therapy (PegIntron) for chronic hepatitis B. “Our
The alpha interferon, BLX-883, will be the first product manufactured using Biolex’ proprietary LEX System to enter the clinic. The study is designed to evaluate safety, pharmacokinetics and